Amides

3,5-Dichlorobenzenesulfonamide is a drug that inhibits bacterial growth by binding to the dihydropteroate synthase enzyme and blocking the synthesis of folic acid. This drug has been shown to be active against methicillin-resistant Staphylococcus aureus (MRSA) and other drug-resistant bacteria. 3,5-Dichlorobenzenesulfonamide is an analog of sulfa drugs, which are also used in the treatment of staphylococcal infections. It is not active against Enterococcus faecium and Streptococcus pneumoniae, two types of bacteria that are resistant to sulfa drugs. 3,5-Dichlorobenzenesulfonamide binds to the vancomycin resistance protein (VANR) as well as other bacterial proteins with high affinity. The VANR protein is important for cell wall synthesis in Gram-positive bacteria such as

(1S)-(+)-10-Camphorsulfonamide is a chiral molecule that can be used as an intermediate in the synthetic process of camphor. It has been shown to be effective against viruses and bacteria, such as influenza virus and Escherichia coli. (1S)-(+)-10-Camphorsulfonamide is also a glyceric compound with a molecular weight of 172.2 g/mol and is soluble in organic solvents. The synthesis of (1S)-(+)-10-camphorsulfonamide has been achieved by the reaction of aziridine with chloride in the presence of copper complex at room temperature. This reaction was found to be exothermic, producing a dipole stabilized molecule with an enthalpy change of -27.8 kJ/mol.

Please enquire for more information about N-Methyl-4-[(methylamino)methyl]benzamide including the price, delivery time and more detailed product information at the technical inquiry form on this page

N-(2-Fluoroethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide (NFEI) is a radiopharmaceutical that is used to detect hypoxic tumor tissue in patients with cancer. It has been shown to be effective at inhibiting the growth of cancer cells and can identify the sites of cancerous cells in vivo. NFEI has high lipophilicity and can be taken up by tumor tissue more easily than healthy tissue, making it an excellent candidate for use in positron emission tomography imaging. This compound is being evaluated as a potential new therapy for cancer treatment.

Please enquire for more information about 3-{5-[(Propylamino)methyl]-1,2,4-oxadiazol-3-yl}benzamide including the price, delivery time and more detailed product information at the technical inquiry form on this page

Cyclic amide